Romidepsin is effective and well-tolerated in patients >= 60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): Analysis from phase 2 trials Meeting Abstract
| Authors: | Shustov, A. R.; Coiffier, B.; Horwitz, S. M.; Sokol, L.; Pro, B.; Nielsen, T.; Wolfson, J.; Balser, B. E.; Eisch, R.; Popplewell, L.; Prince, M.; Allen, S. L.; Piekarz, R.; Bates, S. E. |
| Abstract Title: | Romidepsin is effective and well-tolerated in patients >= 60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): Analysis from phase 2 trials |
| Meeting Title: | 55th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 122 |
| Issue: | 21 |
| Meeting Dates: | 2013 Dec 7-10 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2013-11-15 |
| Language: | English |
| ACCESSION: | WOS:000436807100002 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V122.21.4385.4385 |
| Notes: | Meeting Abstract: 4385 -- Source: Wos |
